<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet type="text/xsl" href="http://www.icis.com/icisconnect/utility/FeedStylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Chemical industry conversations</title><link>http://www.icis.com/icisconnect/forums/363.aspx</link><description>Have your say about what's happening in the chemical industry. </description><dc:language>en</dc:language><generator>CommunityServer 2008.5 SP2 (Build: 40407.4157)</generator><item><title>Is Mallinckrodt going to an Indian company?</title><link>http://www.icis.com/icisconnect/forums/thread/1728.aspx</link><pubDate>Thu, 28 Aug 2008 16:27:41 GMT</pubDate><guid isPermaLink="false">8e774857-1e25-4730-bdb9-310c4492ad3b:1728</guid><dc:creator>Gaolin</dc:creator><slash:comments>0</slash:comments><comments>http://www.icis.com/icisconnect/forums/thread/1728.aspx</comments><wfw:commentRss>http://www.icis.com/icisconnect/forums/commentrss.aspx?SectionID=363&amp;PostID=1728</wfw:commentRss><description>&lt;p&gt;Says India&amp;#39;s Economic Times:  &amp;quot;ICICI Venture-controlled RFCL (formerly Ranbaxy Fine Chemicals) has emerged as a strong contender to buy the speciality chemicals business of Mallinckrodt Baker, a division of healthcare giant Covidien, in a deal which could be valued at around $450 million, industry sources said. The transaction is in the final stages of due diligence and could be finalised in about two weeks.&amp;quot; Good idea or trophy?&lt;/p&gt;&lt;div style="clear:both;"&gt;&lt;/div&gt;</description></item></channel></rss>